OXIS International Names David Saloff as Chief Executive Officer

BEVERLY HILLS, Calif., Sept. 6, 2011 /PRNewswire/ -- OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced it has named David Saloff as Chief Executive Officer.  Mr. Saloff was appointed to the Company's Board of Directors in June of 2011.

"David's proven ability to move companies from development stage to successful commercialization makes him an outstanding choice to lead OXIS at this time," said Anthony J. Cataldo, Chairman of OXIS International. "In addition to his managerial experience, David has an outstanding track record of effectively raising and deploying capital, and building shareholder value."

Mr. Saloff stated, "OXIS International can become a leader in the nutraceutical and nutritional food industry by leveraging the unique properties and benefits of Ergothioneine, one of the most potent and versatile antioxidants yet discovered.  I look forward to working with OXIS' strong network of scientific advisors and marketing partners to continue the development and commercialization of our ERGO-based products."

Mr. Saloff is a successful entrepreneur in the healthcare industry, having founded three companies, two of which went public and a third that was sold to a leading healthcare products company.  In 1991, he founded Electropharmacology, which developed first-generation solid state pulse electromagnetic field therapy devices to treat chronic wounds. Later he assumed the Presidency of LifeWaves International, a health and fitness research and development company based on a revolutionary exercise and lifestyle theory to increase longevity. He also was co-founder and co-chief executive officer of Ivivi Technologies, which developed and manufactured advanced non-drug anti-inflammatory devices for the treatment of chronic and acute wounds and post-surgical pain.  

About OXIS International, Inc.

OXIS International, Inc. is a long-established but recently revitalized biotechnology Company developing multiple proprietary, natural substance-based products focused on oxidative stress and inflammation, which are associated with the negative effects of free radicals and reactive oxygen species.  The Company's consumer product portfolio includes dietary supplements and is expected ultimately to include functional foods and beverages, skin care and other personal care products, and animal health products.  Specifically, OXIS is emphasizing the unique properties of L-Ergothioneine, a highly potent, patent-protected and versatile antioxidant. The Company has completed a strategic financing agreement with its primary product development and manufacturing partner, Gemini Pharmaceuticals, launched its first product, ErgoFlex for joint pain relief and overall joint health, and announced a joint venture with engage:BDR, a global leader in online sales and marketing.  For more information, please visit www.oxis.com

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "potential" or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risks of obtaining possibly required regulatory approvals, the timing of product introductions, the level of market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.  Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE OXIS International, Inc.